Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
M.D. Anderson Cancer Center
BioNTech SE
Kaiser Permanente
Medicine Invention Design, Inc
National Cancer Institute (NCI)
Pfizer
Bristol-Myers Squibb
Swiss Cancer Institute
Mirati Therapeutics Inc.
Canadian Cancer Trials Group
AbbVie
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Henlius Biotech
Hoffmann-La Roche
NRG Oncology
Cancer Research UK
AbbVie
SWOG Cancer Research Network
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
TJ Biopharma Co., Ltd.
Eikon Therapeutics
SWOG Cancer Research Network
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Rigshospitalet, Denmark
Shanghai Henlius Biotech
RenJi Hospital
SWOG Cancer Research Network
Cancer Research UK
Cancer Research UK
Sichuan Baili Pharmaceutical Co., Ltd.
Alpha Biopharma (Jiangsu) Co., Ltd.
Medicine Invention Design, Inc
Betta Pharmaceuticals Co., Ltd.
Peking Union Medical College Hospital
Hansoh BioMedical R&D Company
Medicine Invention Design, Inc
Shanghai Chest Hospital
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
PhytoHealth Corporation
SWOG Cancer Research Network
Intergroupe Francophone de Cancerologie Thoracique
Canadian Cancer Trials Group
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University
Hunan Province Tumor Hospital
Guy's and St Thomas' NHS Foundation Trust